AtriCure Q3 2026 earnings

ATRC · 2026-11-03 16:00 AMC ET · 8-K on SEC · 10-Q on SEC

Revenue growth accelerated to 15.0% year over year, with gross margin expanding to 77.3% and adjusted EBITDA reaching $26.8 million.

Headline numbers

MetricActualYoYQoQ8-K location
Revenue$154.5M+15.0%+0.6%Ex. 99.1, income statement
EPS (GAAP)$0.08+0.09-0.10Ex. 99.1, income statement
EPS (adjusted)$0.18+0.170.00Ex. 99.1, income statement
Net income$4.1M$4.3M-$5.0MEx. 99.1, income statement
Adj. EBITDA$26.8M+51%-0.5MEx. 99.1, income statement
Adj. EBITDA margin17.3%+1.5 pp-0.1 ppEx. 99.1, income statement

Revenue breakdown

SegmentActualYoYShare of revenueNote
United States$128.0M+17.1%82.9%Growth driven by cryoSPHERE MAX, EnCompass clamp, and AtriClip devices
International$26.4M+5.8%17.1%Growth in all franchises

Margins and costs

  • Gross margin 77.3% (prior 77.2%, change +0.1 pp)
  • Operating expenses $115.0M (+13.0% YoY)
  • One-offs in the quarter Acquired in-process research & development expense: $4.5M; Income tax benefit: $47K
  • Effective tax rate 1.2% (prior-year 3.0%, year-to-date 5.1%)
  • Non-GAAP bridge Adds back depreciation and amortization ($5.5M), share-based compensation ($12.5M), and non-recurring IPR&D ($4.5M).

KPIs

MetricActualPrior quarterPrior yearChange
Adjusted EBITDA$26.8M$27.3M$17.8M+51% YoY, -0.5% QoQ
Cash and cash equivalents$187.0M$167.4MN/A+$19.6M

Guidance

MetricGuidePrior guideChange
Full year 2026 revenue$606M - $610M$602M - $610MRaised lower bound by $4M
Full year 2026 adjusted EBITDA$91M - $94M$85M - $89MRaised lower bound by $6M
Full year 2026 net income per share$0.21 - $0.27$0.05 - $0.13Raised lower bound by $0.16
Full year 2026 adjusted earnings per share$0.40 - $0.46$0.24 - $0.32Raised lower bound by $0.16

What drove it

  • Revenue story U.S. revenue grew 17.1% to $128.0M; International revenue grew 5.8% to $26.4M. Minimally invasive ablation sales declined due to reduced Hybrid procedures as physicians adopt PFA catheters.
  • EPS story GAAP EPS improved to $0.08 from a loss of $0.01 YoY, driven by higher revenue and improved margins, offset by higher share count.
  • One-off check Acquired in-process research & development expense of $4.5M (non-recurring).

The good

  • Revenue growth accelerated to 15.0% YoY
  • Adjusted EBITDA reached $26.8M (+51% YoY)
  • Gross margin expanded to 77.3%
  • Full year guidance raised across all metrics

The bad

  • Minimally invasive ablation sales declined
  • Net income decreased QoQ to $4.1M

The ugly

  • none

Open questions

  • What is the magnitude of the decline in Minimally invasive ablation sales?
  • What is the impact of the shift to PFA catheters on long-term revenue mix?
Full release

AtriCure (ATRC) earnings release, November 3, 2026

AtriCure, Inc. (ATRC) · Form 8-K, Item 2.02 · Filed · SEC filing

November 3, 2026

AtriCure Reports Third Quarter 2026 Financial Results

• Third Quarter 2026 worldwide revenue of $154.5 million, an increase of 15.0% year over year

• Profitability expansion in the Third Quarter 2026, with net income of $4.1 million and adjusted EBITDA of $26.8 million

MASON, Ohio, November 3, 2026 – AtriCure, Inc.

(

Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced third quarter 2026 financial results.

“Our third quarter results demonstrate the strength of our broad portfolio and our team’s disciplined execution,” said Michael Carrel, President and Chief Executive Officer. “Adoption of our innovative technologies is driving strong growth and expanding profitability, while the rapid progress of our BoxX-NoAF clinical trial reinforces our confidence in the opportunities ahead. We are well positioned to extend our leadership in cardiac surgery and post-operative pain management, creating lasting value for patients and our shareholders.”

Third Quarter 2026 Financial Results

Worldwide revenue for the third quarter 2026 was $154.5 million, an increase of 15.0% over third quarter 2025 revenue (15.1% on a constant currency basis). U.S. revenue was $128.0 million, an increase of $18.7 million or 17.1%, compared to the third quarter 2025. U.S. revenue growth was driven by sales of our cryoSPHERE®

MAX™ probe for post-operative pain management, EnCompass® clamp in open ablation, and AtriClip FLEX-Mini® and AtriClip PRO-Mini® devices for appendage management. Minimally invasive ablation sales declined during the quarter from continued reduction in Hybrid procedures as physicians adopt PFA catheters to treat patients. International revenue increased $1.4 million or 5.8% (6.1% on a constant currency basis) to $26.4 million, with growth in all franchises.

Gross profit for the third quarter 2026 was $119.4 million compared to $101.3 million for the third quarter 2025. Gross margin was 77.3% for the third quarter 2026, an increase of 180 basis points from the third quarter 2025, driven primarily by favorable product and geographic mix. Income from operations for the third quarter 2026 was $4.4 million, compared to $0.2 million for the third quarter 2025. Basic and diluted net income per share was $0.08 for the third quarter 2026, compared to basic and diluted net loss per share of $0.01 for the third quarter 2025.

Adjusted EBITDA for the third quarter 2026 was $26.8 million, an increase of $9.0 million or 51% from the third quarter 2025. For the third quarter 2026, adjusted earnings per share was $0.18, compared to $0.01 adjusted loss per share for the third quarter 2025.

Constant currency revenue, adjusted EBITDA and adjusted earnings (loss) per share are non-GAAP financial measures. We discuss these non-GAAP financial measures and provide reconciliations to GAAP measures later in this release.

2026 Financial Guidance

Full year 2026 revenue is now projected to be approximately $606 million to $610 million, and management also projects full year 2026 adjusted EBITDA of approximately $91 million to $94 million. Full year 2026 net income per share is expected to be in the range of $0.21 to $0.27 and adjusted earnings per share of approximately $0.40 to $0.46. Additionally, management expects continued positive cash generation for 2026.

Conference Call

AtriCure will host a conference call at 4:30 p.m. Eastern Time on Tuesday, November 3, 2026, to discuss third quarter 2026 financial results. To access the webcast, please visit the Investors page of AtriCure’s corporate website at https://ir.atricure.com/events-and-presentations/events. Participants are encouraged to register more than 15 minutes before the webcast start time. A replay of the presentation will be available for 90 days following the presentation.

About

AtriCure

AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 59 million people worldwide. Surgeons around the globe use AtriCure technologies for the treatment of Afib, reduction of Afib related complications, and post-operative pain management. AtriCure’s Isolator®

Synergy™ Ablation System is the first medical device to receive FDA approval for the treatment of persistent Afib. AtriCure’s AtriClip®

Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide. AtriCure’s Hybrid AF™ Therapy is a minimally invasive procedure that provides a lasting solution for long-standing persistent Afib patients. AtriCure’s cryoICE cryoSPHERE® and cryoXT® probes are cleared for temporary ablation of peripheral nerves to block pain, providing pain relief in cardiac, thoracic and amputation procedures. For more information, visit AtriCure.com or follow us on X @AtriCure.

Financial statements

Income Statement

Three Months Ended September 30, — (Unaudited)

Three Months Ended September 30, – 2026Three Months Ended September 30, – 2025Nine Months Ended September 30, – 2026Nine Months Ended September 30, – 2025
United States Revenue:
Open ablation43,00335,592122,968105,368
Minimally invasive ablation5,3897,42817,80623,747
Pain management28,05720,83777,47459,275
Appendage management51,60045,450151,594132,649
Total United States128,049109,307369,842321,039
International Revenue:
Open ablation11,17810,85231,93730,196
Minimally invasive ablation1,9031,8625,8366,247
Pain management2,4402,0806,8105,902
Appendage management10,88010,16834,87830,644
Total International26,40124,96279,46172,989
Total revenue154,450134,269449,303394,028
Cost of revenue35,10032,937102,01398,586
Gross profit119,350101,332347,290295,442
Operating expenses:
Research and development expenses32,11622,89282,75374,704
Selling, general and administrative expenses82,88178,232249,993232,676
Total operating expenses114,997101,124332,746307,380
Income (loss) from operations4,35320814,544-11,938
Other expense, net-336-294-707-585
Income (loss) before income tax expense4,017-8613,837-12,523
Income tax expense (benefit)-47181710681
Net income (loss)4,064-26713,127-13,204
Basic net income (loss) per share0.08-0.010.27-0.28
Diluted net income (loss) per share0.08-0.010.27-0.28
Weighted average shares used in computing net income (loss) per share:
Basic48,89347,92048,63347,680
Diluted49,83147,92049,38547,680

Income Statement

Three Months Ended September 30, — Reconciliation of Non-GAAP Adjusted Income (Adjusted EBITDA)

Three Months Ended September 30, – 2026Three Months Ended September 30, – 2025Nine Months Ended September 30, – 2026Nine Months Ended September 30, – 2025
Net income (loss), as reported4,064-26713,127-13,204
Income tax expense (benefit)-47181710681
Other expense, net336294707585
Depreciation and amortization expense5,4745,16916,05515,424
Share-based compensation expense12,47812,42436,06433,425
Acquired in-process research & development expense4,5004,5005,000
Non-GAAP adjusted income (adjusted EBITDA)26,80517,80171,16341,911

Balance Sheet

(Unaudited)

September 30, 2026December 31, 2025
Current assets:
Cash and cash equivalents187,031167,428
Accounts receivable, net76,12866,653
Inventories87,31078,492
Prepaid and other current assets12,9219,944
Total current assets363,390322,517
Property and equipment, net66,66739,123
Operating lease right-of-use assets5,7116,868
Goodwill and intangible assets, net275,656282,807
Other noncurrent assets6,1122,864
Total Assets717,536654,179
Current liabilities:
Accounts payable and accrued liabilities80,24578,399
Other current liabilities3,7273,121
Total current liabilities83,97281,520
Long-term debt61,00061,865
Finance and operating lease liabilities32,10511,516
Other noncurrent liabilities7,2357,343
Total Liabilities184,312162,244
Stockholders' Equity:
Common stock5150
Additional paid-in capital933,234904,522
Accumulated other comprehensive income15566
Accumulated deficit-400,076-413,203
Total Stockholders' Equity533,224491,935
Total Liabilities and Stockholders' Equity717,536654,179

Cash Flow

From the 10-Q · Nine Months Ended September 30, — (Unaudited)

Nine Months Ended September 30, – 2026Nine Months Ended September 30, – 2025
Cash flows from operating activities:
Net income (loss)13,127-13,204
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Share-based compensation expense36,06433,425
Depreciation8,9049,093
Amortization of intangible assets7,1516,331
Amortization of deferred financing costs323359
Acquired in-process research and development expense4,5005,000
Other non-cash adjustments1,727726
Changes in operating assets and liabilities:
Accounts receivable-9,996-1,855
Inventories-9,083-2,711
Other current assets-3,058-1,687
Accounts payable5,898315
Accrued liabilities-3,0643,292
Other noncurrent assets and liabilities-3,975-1,777
Net cash provided by operating activities48,51837,307
Cash flows from investing activities:
Purchases of property and equipment-14,006-7,448
Acquisitions, including in-process research and development-4,500-5,000
Proceeds from capital grant500
Net cash used in investing activities-18,506-11,948
Cash flows from financing activities:
Payments on debt, leases and financing obligation-1,854-880
Proceeds from financing obligation6,250

Forward-Looking Statements... (truncated)n regulatory clearances and approvals for our products and launching our products; impacts of rising healthcare costs; our ability to comply with extensive FDA regulations; the timing of and ability to obtain third party payor reimbursement of procedures utilizing our products; unfavorable publicity; the potential impact of any acquisitions, mergers, dispositions, joint ventures or investments we may make; disruptions to our manufacturing operations; the impact of tariffs or other restrictive trade measures; our failure to properly manage growth; disruptions of critical information systems or material breaches in the security of our systems; our ability to manage our intellectual property rights to provide meaningful protection; fluctuation of quarterly financial results; fluctuations in foreign currency exchange rates; reliance on third party manufacturers and suppliers; and litigation, administrative or other proceedings. These risks and uncertainties, as well as others, are discussed in greater detail in our filings with the Securities and Exchange Commission ("SEC"), including our Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on February 19, 2026, and our subsequent Quarterly Reports on Form 10-Q. There may be additional risks of which we are not presently aware or that we currently believe are immaterial which could have an adverse impact on our business. Any forward-looking statements are based on our current expectations, estimates and assumptions regarding future events and are applicable only as of the dates of such statements. We make no commitment to revise or update any forward-looking statements in order to reflect events or circumstances that may change, except as required by law.

Use of Non-GAAP Financial Measures

To supplement AtriCure’s condensed consolidated financial statements prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP, AtriCure provides certain non-GAAP financial measures in this release as supplemental financial metrics.

Revenue reported on a constant currency basis is a non-GAAP measure, calculated by applying previous period foreign currency exchange rates to each of the comparable periods. Management analyzes revenue on a constant currency basis to better measure the comparability of results between periods. Because changes in foreign currency exchange rates have a non-operating impact on revenue, the Company believes that evaluating growth in revenue on a constant currency basis provides an additional and meaningful assessment of revenue for both management and investors.

Adjusted EBITDA is calculated as net income (loss) before other income/expense (including interest), income tax expense, depreciation and amortization expense, share-based compensation expense, and non-recurring charges that are not reflective of the operational results of the Company’s core business and may affect comparability of results period-over-period. Non-recurring charges include acquisition costs, acquired-in-process research and development (IPR&D) and related milestone payments arising from asset acquisitions, legal settlement costs, impairment of intangible assets and changes in fair value of contingent consideration liabilities.

Management believes in order to properly understand short-term and long-term financial trends, investors may wish to consider the impact of these excluded items in addition to GAAP measures. The excluded items vary in frequency and/or impact on our continuing results of operations and management believes that the excluded items are typically not reflective of our ongoing core business operations and financial condition. Further, management uses adjusted EBITDA for both strategic and annual operating planning. A reconciliation of adjusted EBITDA reported in this release to the most comparable GAAP measure for the respective periods appears in the table captioned “Reconciliation of Non-GAAP Adjusted Income (Adjusted EBITDA)” later in this release.

Adjusted earnings (loss) per share is a non-GAAP measure which calculates the net income (loss) per share before non-cash adjustments in fair value of contingent consideration liabilities, acquired IPR&D and related milestone payments arising from asset acquisitions, legal settlement costs, impairment of intangible assets and debt extinguishment.

The non-GAAP financial measures used by AtriCure may not be the same or calculated in the same manner as those used and calculated by other companies. Non-GAAP financial measures have limitations as analytical tools and should not be considered in isolation or as a substitute for AtriCure’s financial results prepared and reported in accordance with GAAP. We urge investors to review the reconciliation of these non-GAAP financial measures to the comparable GAAP financial measures included in this press release, and not to rely on any single financial measure to evaluate our business.

CONTACTS:

Angie Wirick

AtriCure, Inc.

Chief Financial Officer

(513) 755-5334 awirick@atricure.com

Marissa Bych

Gilmartin Group

Investor Relations

(415) 937-5402 marissa@gilmartinir.com

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · AtriCure earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.